View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:
Link to full program, including associated downloadable slidesets:
https://www.clinicaloptions.com/oncology/programs/ret-positive-cancers
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)
Nelson F. Sanchez, MD
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Nelson F. Sanchez, MD
Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.